Education

301 Hospital Postgraduate Academy, Master Of Medicine
Second Military Medical University, Bachelor Of Medicine

Professional Experience

2001-2005: Worked at Jeekai & Partners
2005-2007: Manager, Patent & Strategic Collaboration Department, Novozymes (China) Investment Co., Ltd.
2008-2012: Director, Intellectual Property Department, DSM (China)
2012: Joined Shangcheng & Partners

Technical Areas

Molecular Biology, Medicine, Pharmaceuticals, Biochemistry, Polymer Chemistry, Microbiology, Organic Chemistry, etc.

Bar Admissions/ Qualifications

Patent Attorney, 2004
Patent Litigation Attorney, 2016

Membership

All China Patent Attorneys Association(ACPAA)
Board Member, Capital Intellectual Property Services Association(CIPSA)
AIPPI

Languages

Chinese, English

Profile

Xiaoman is a Chinese Patent Attorney specializing in pharmaceutical, chemistry & biochemistry sector since 2001 where she started her IP profession as patent attorney at Jeekai & Partners where she prepared, drafted and prosecuted domestic patent applications as well as foreign patent applications. Before joining Shangcheng & Partners in 2012, she worked with European companies as IP head of China for 7 years. The combination of her extensive IP experience in private practice and deep involvement in the use of IP in industry as IP head for China provides unique understanding for the balance among the IP needs, business needs and the IP practice of China.
Xiaoman specializes in patent drafting, patent prosecution, FTO analysis, patent validity analysis, patent infringement, pre-litigation opinion, patent portfolio management, IP strategy making, IP due diligence in M&A, patent infringement litigation, patent validity & patent re-examination and related administrative litigations, trade secret protection with a focus on pharmaceutical and chemistry & biochemistry sector.
Xiaoman conducts lectures and seminars on several topics in the intellectual property field for both attorneys and business people. Topics cover, for example, “Patent litigation in China”, “Managing patent portfolio globally”, “Inventor Remuneration/Reward policy in China”, etc.